For five years, Alzheimer’s slowly stripped away a Japanese-American woman’s ability to talk multiple syllable at a time. The lady, now in her 80s, was diagnosed roughly a decade ago, and her condition steadily worsened. She struggled to walk and recognize members of the family.
Then, under medical supervision, she took a big dose of mushrooms containing the psychedelic psilocybin. Inside three days, her symptoms had improved. She began spontaneously recounting memories and initiating conversations in full sentences. Her alertness returned, and he or she could move around independently.
Per week later, she was recognizing members of the family, asking where they were, and mentioning cars that appear misplaced.
Psilocybin has been maligned for many years. But renewed interest in its unique effects on the brain has pushed it into mainstream research. Early studies suggest it could help treat depression, anxiety, addiction, post-traumatic stress disorder, and other psychiatric conditions. A clinical trial is underway to gauge whether it could actually protect the aging brain.
The case study, conducted in Brazil, adds to that momentum. The team emphasizes that it describes a single patient and is only observational. Due to severity of her disease, they might not perform brain scans, measure biomarkers, or conduct standard cognitive tests. Exactly why her symptoms improved stays unknown.
Even so, they propose that psilocybin could have temporarily unlocked brain function in late-stage Alzheimer’s, potentially allowing dormant neural networks to rewire.
Brain Under Fire
Alzheimer’s is usually synonymous with memory loss. Sadly, symptoms range far beyond forgetting names or misplacing glasses.
Because the disease progresses, people steadily struggle to seek out the suitable words or follow conversations. Their ability to tackle on a regular basis tasks—cooking, managing funds, planning ahead—erodes. Depression, irritability, and anxiety often emerge. Over time, their personalities flatten, leaving them less outgoing, engaged, or empathetic.
These stories are far too common. Based on the World Health Organization, roughly 57 million people worldwide were living with dementia in 2021. Alzheimer’s may account for as much as 70 percent of cases. As populations age, that number is anticipated to climb.
Alzheimer’s has no single cause. Genetics likely play a job. Some gene variants are linked to early-onset types of the disease, an area scientists at the moment are tackling with gene therapy.
One other hallmark of the disease is a buildup of abnormal protein clumps, or plaques, in and around neurons, which disrupts normal function and wrecks their ability to form neural networks supporting memory and cognition. Years of efforts to remove plaques have largely failed, though the FDA recently approved two antibodies that reduce them and modestly slow cognitive decline.
Then there’s inflammation. In Alzheimer’s, the brain’s immune system can develop into overactive. Fairly than responding only to wreck, inflammation drives disease progression, spreading toxic protein clumps through the brain and further damaging its ability to form latest connections.
Here’s where psilocybin, the energetic ingredient in magic mushrooms, may help. Psilocybin alters serotonin signaling, a brain chemical involved in mood, perception, and cognition. But its effects likely extend far beyond that.
Studies in mice suggest the chemical boosts the brain’s ability to rewire, a process often called neuroplasticity. Human brain imaging studies have found that the psychedelic temporarily reorganizes communication between large brain networks, changing how distant regions interact. In some participants, supervised treatment has been linked to greater cognitive flexibility, deeper self-reflection, and improved well-being.
Other studies hint at a protective role. Psilocybin triggers the discharge of “nurturing” proteins. This process helps neurons survive stress and extend their branching connections. It’s these delicate structures that construct up neural networks, they usually wither away during depression, aging, and dementia. Contained in the hippocampus, a region crucial for learning and memory, the drug stimulates the birth of latest neurons, at the very least in mice.
Given its positive effects on brain plasticity, psilocybin is now being tested in multiple psychiatric disorders characterised by unusually rigid patterns of brain activity. Older adults remain largely absent from these studies, though they may benefit essentially the most.
Tale of One
Before treatment, the lady struggled with on a regular basis life. For five years, she could communicate using only single-syllable words. Her mobility was severely limited, and he or she struggled with incontinence.
With the consent of her caretaker, she received five grams of the Enigma strain of Psilocybe cubensis. Because psilocybin levels vary widely between mushrooms, the precise dose is unknown. But in comparison with other clinical trials, it was relatively high.
The team selected the dose “based on prior experiential observations regarding depth and duration of psychedelic-induced neurobehavioral effects,” wrote the team.
Initially, the lady fell right into a deep sleep-like state accompanied by elevated body temperature and heavy sweating. Roughly 19 hours later, she suddenly awoke and commenced talking to caregivers in complete sentences, recounting memories from her life. The conversation lasted around 4 hours.
Over the next days, she became increasingly alert and engaged. She recognized members of the family, regained mobility, and will pick matching clothes to decorate herself. Per week later, she was noticing small details in her environment, including a rental automotive parked outside the home. When a member of the family was absent, she asked, “Where did Celso go?” She also appeared to rediscover her love of social interactions, making eye contact, smiling back, and actively starting conversations.
A month after the initial session, she returned for a second supervised dose of three grams. After the second dose, she became much more verbally expressive, displayed a humorousness, and described memories of browsing together with her son on a peaceful island. Throughout the trial, the drug alleviated incontinence and improved her quality of life.
The outcomes include major caveats. The improvements were observational and largely reported by caregivers, leaving room for bias. The team didn’t administer standardized tests for cognition, dementia, depression, and anxiety. Nor did they perform brain scans or monitor sleep, making it not possible to find out what brain changes were behind her apparent “awakening.”
“Causality can’t be established, and spontaneous fluctuations inherent to neurodegenerative disease can’t be completely excluded,” they wrote.
However the study touches on a provocative idea in Alzheimer’s: Cognitive reserve. The speculation proposes some people can tolerate greater levels of harm to the brain and proceed functioning despite significant damage. Psilocybin could have temporarily tapped into these reserves, allowing dormant neural circuits to have interaction and rewire to compensate for impaired ones. The hypothesis is extremely speculative and desires to be rigorously tested.
Meanwhile, a clinical trial is investigating whether psilocybin can reduce depression and improve quality of life in individuals with mild cognitive impairment or early Alzheimer’s disease, moving the needle beyond a single case study.
For one family, nonetheless, the advantages are already substantial. At a follow-up visit, the lady spontaneously said to everyone within the room, “It’s nice to return here.”